|
DE19608753C1
(de)
*
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
WO2004104185A1
(en)
*
|
2003-05-08 |
2004-12-02 |
Xcyte Therapies, Inc. |
Generation and isolation of antigen-specific t cells
|
|
US20070032570A1
(en)
*
|
2003-11-11 |
2007-02-08 |
Canon Kabushiki Kaisha |
Ink comprising a block copolymer dispersing agent having a hydrophilic and a hydrophobic segment and an ink-applying process and apparatus using the same
|
|
US20050281786A1
(en)
*
|
2004-06-18 |
2005-12-22 |
David Poulsen |
AAV mediated gene delivery to cochlear cells
|
|
US20100080784A1
(en)
*
|
2008-09-12 |
2010-04-01 |
Torrey Pines Institute For Molecular Studies |
Methods for treating cachexia and lymphopenia
|
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
IL292038B2
(en)
|
2014-04-23 |
2024-12-01 |
Juno Therapeutics Inc |
Methods for enriching or producing immune cell populations for adoptive therapy
|
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
BR112017008042A2
(pt)
|
2014-10-20 |
2017-12-26 |
Juno Therapeutics Inc |
métodos e composições para dosagem em terapia de célula adotiva
|
|
JP6740234B2
(ja)
|
2014-11-05 |
2020-08-12 |
ジュノー セラピューティクス インコーポレイテッド |
形質導入および細胞プロセシングのための方法
|
|
EP3227323B1
(en)
|
2014-12-03 |
2020-08-05 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
MX2017015239A
(es)
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
|
KR102908806B1
(ko)
|
2015-10-22 |
2026-01-07 |
주노 테라퓨틱스 게엠베하 |
세포의 배양 방법 및 이를 위한 키트와 장치
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
US12214054B2
(en)
|
2015-11-30 |
2025-02-04 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
US20200297760A1
(en)
|
2015-12-03 |
2020-09-24 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
|
WO2017096331A1
(en)
|
2015-12-04 |
2017-06-08 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
MA43759A
(fr)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
Procédés de conception adaptative d'un régime de traitement et traitements associés
|
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
|
CN109476743A
(zh)
|
2016-03-22 |
2019-03-15 |
西雅图儿童医院(以西雅图儿童研究所名义营业) |
预防或缓解毒性的早期干预方法
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
WO2017210689A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
|
WO2017214207A2
(en)
|
2016-06-06 |
2017-12-14 |
Juno Therapeutics, Inc. |
Methods for the treatment of b cell malignancies using adoptive cell therapy
|
|
JP7054397B2
(ja)
|
2016-06-27 |
2022-04-13 |
ジュノー セラピューティクス インコーポレイテッド |
Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
|
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
JP7295795B2
(ja)
|
2016-07-29 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
免疫調節ポリペプチドならびに関連する組成物および方法
|
|
MA45784A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
|
|
MX2019002765A
(es)
|
2016-09-12 |
2019-05-09 |
Juno Therapeutics Inc |
Montajes de bolsa de biorreactor de perfusion.
|
|
CN110087657A
(zh)
|
2016-09-28 |
2019-08-02 |
阿托莎遗传股份有限公司 |
过继细胞治疗的方法
|
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
|
EP3525803B1
(en)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
CA3042049A1
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
|
MA46716A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
|
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
JP2019536460A
(ja)
|
2016-12-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃａｒ−ｔ細胞の調節方法
|
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
|
US11590167B2
(en)
|
2016-12-03 |
2023-02-28 |
Juno Therapeutic, Inc. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
|
EP3571221A2
(en)
|
2017-01-20 |
2019-11-27 |
Juno Therapeutics GmbH |
Cell surface conjugates and related cell compositions and methods
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
MX2019010171A
(es)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
|
|
CN110913690A
(zh)
|
2017-03-14 |
2020-03-24 |
朱诺治疗学股份有限公司 |
用于低温储存的方法
|
|
BR102018006205A2
(pt)
|
2017-03-28 |
2021-03-23 |
Cell Design Labs, Inc. |
Polipeptídeos quiméricos e métodos de alterar a localização da membrana dos mesmos
|
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
|
CN110709700A
(zh)
|
2017-04-14 |
2020-01-17 |
朱诺治疗学股份有限公司 |
评估细胞表面糖基化的方法
|
|
AU2018260380B2
(en)
|
2017-04-27 |
2025-02-13 |
Juno Therapeutics Gmbh |
Oligomeric particle reagents and methods of use thereof
|
|
PL3618842T3
(pl)
|
2017-05-01 |
2024-02-19 |
Juno Therapeutics, Inc. |
Kombinacja terapii komórkowej i związku immunomodulującego
|
|
IL327498A
(en)
|
2017-06-02 |
2026-05-01 |
Juno Therapeutics Inc |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
EP3631468A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
CN110997902B
(zh)
|
2017-06-20 |
2021-11-30 |
居里研究所 |
Suv39h1缺陷的免疫细胞
|
|
CN111050545A
(zh)
|
2017-06-29 |
2020-04-21 |
朱诺治疗学股份有限公司 |
评估与免疫疗法相关的毒性的小鼠模型
|
|
EP4549554A3
(en)
|
2017-07-29 |
2025-08-06 |
Juno Therapeutics, Inc. |
Reagents for expanding cells expressing recombinant receptors
|
|
KR102755437B1
(ko)
|
2017-08-09 |
2025-01-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
|
|
EP4516896A3
(en)
|
2017-08-09 |
2025-05-14 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
|
MA50079A
(fr)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics Inc |
Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
|
JP7357626B2
(ja)
|
2017-11-01 |
2023-10-06 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞の治療用組成物を生成するためのプロセス
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
|
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
US20200330983A1
(en)
|
2017-11-10 |
2020-10-22 |
Juno Therapeutics, Inc. |
Closed-system cryogenic vessels
|
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
|
BR112020011223A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
marcadores fenotípicos para terapia celular e mé-todos relacionados
|
|
AU2018379091A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
EP3724225A1
(en)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
WO2019126358A1
(en)
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
|
US12509492B2
(en)
|
2018-01-19 |
2025-12-30 |
Duke University |
Genome engineering with CRISPR-Cas systems in eukaryotes
|
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
US12280119B2
(en)
|
2018-03-23 |
2025-04-22 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
CN112585277A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
表达重组受体的t细胞、相关多核苷酸和方法
|
|
BR112020022185A2
(pt)
|
2018-05-03 |
2021-02-02 |
Juno Therapeutics Inc |
terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
|
|
CN112368298A
(zh)
|
2018-06-22 |
2021-02-12 |
凯德药业股份有限公司 |
嵌合跨膜蛋白及其用途
|
|
BR112021002390A2
(pt)
|
2018-08-09 |
2021-05-11 |
Juno Therapeutics Inc |
processos para gerar células modificadas e suas composições
|
|
CN112805378A
(zh)
|
2018-08-09 |
2021-05-14 |
朱诺治疗学股份有限公司 |
用于评估整合核酸的方法
|
|
JP7504891B2
(ja)
|
2018-09-11 |
2024-06-24 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞組成物のマススペクトロメトリー分析のための方法
|
|
CA3115298A1
(en)
|
2018-10-12 |
2020-04-16 |
Theradaptive, Inc. |
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
|
|
WO2020089343A1
(en)
|
2018-10-31 |
2020-05-07 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
CN119569895A
(zh)
|
2018-11-01 |
2025-03-07 |
朱诺治疗学股份有限公司 |
G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
|
|
US12473345B2
(en)
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
US20210393691A1
(en)
|
2018-11-06 |
2021-12-23 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
|
EP4427810A3
(en)
|
2018-11-30 |
2024-12-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
KR20210110811A
(ko)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
|
|
EA202192103A1
(ru)
|
2019-01-29 |
2021-12-15 |
Джуно Терапьютикс, Инк. |
Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
|
|
TWI887234B
(zh)
|
2019-04-14 |
2025-06-21 |
美國公爵大學 |
治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除
|
|
SG11202111372VA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
US20220228101A1
(en)
|
2019-06-07 |
2022-07-21 |
Juno Therapeutics, Inc. |
Automated t cell culture
|
|
SG11202113356XA
(en)
|
2019-06-12 |
2021-12-30 |
Juno Therapeutics Inc |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
CN114391021B
(zh)
|
2019-06-21 |
2026-01-16 |
凯德药业股份有限公司 |
TGF-β受体和使用方法
|
|
EP4003407A1
(en)
|
2019-07-23 |
2022-06-01 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
|
|
CN114600172A
(zh)
|
2019-08-30 |
2022-06-07 |
朱诺治疗学股份有限公司 |
用于将细胞分类的机器学习方法
|
|
EP4025698A1
(en)
|
2019-09-03 |
2022-07-13 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
|
US20220372516A1
(en)
|
2019-10-11 |
2022-11-24 |
Takara Bio Inc. |
siRNA EXPRESSION VECTOR
|
|
MX2022005145A
(es)
|
2019-10-30 |
2022-06-29 |
Juno Therapeutics Gmbh |
Dispositivos de estimulación y/o selección celular y método de uso.
|
|
US20220412954A1
(en)
|
2019-11-05 |
2022-12-29 |
Juno Therapeutics, Inc. |
Methods of determining attributes of therapeutic t cell compositions
|
|
EP4054623A1
(en)
|
2019-11-07 |
2022-09-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione
|
|
WO2021113780A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
|
WO2021113776A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
|
EP4070097A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
|
|
US12665049B2
(en)
|
2020-01-17 |
2026-06-23 |
AskBio, Inc. |
Systems and methods for synthetic regulatory sequence design or production
|
|
US20230071910A1
(en)
|
2020-01-24 |
2023-03-09 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
CA3169672A1
(en)
|
2020-02-12 |
2021-08-19 |
Juno Therapeutics, Inc. |
Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
|
JP2023519099A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
|
|
IL297147B1
(en)
|
2020-04-10 |
2026-05-01 |
Juno Therapeutics Inc |
Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
|
|
BR112022020809A2
(pt)
|
2020-04-15 |
2023-02-23 |
Theradaptive Inc |
Composições e métodos para entrega terapêutica direcionada ao osso
|
|
CA3181399A1
(en)
|
2020-04-28 |
2021-11-04 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
|
KR20230024283A
(ko)
|
2020-05-13 |
2023-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
CA3188656A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
JP7886313B2
(ja)
|
2020-07-30 |
2026-07-07 |
アンスティテュ・クリー |
Ｓｏｃｓ１に欠陥のある免疫細胞
|
|
KR20230095918A
(ko)
|
2020-08-05 |
2023-06-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
|
|
WO2022047316A1
(en)
|
2020-08-28 |
2022-03-03 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
US20230374542A1
(en)
|
2020-10-07 |
2023-11-23 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
|
|
WO2022082030A2
(en)
|
2020-10-15 |
2022-04-21 |
Gritstone Bio, Inc. |
Antigen-binding proteins and related methods of use
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
|
WO2022155503A1
(en)
|
2021-01-14 |
2022-07-21 |
Gritstone Bio, Inc. |
Multi-specific antibodies and methods of use
|
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
|
US20240168012A1
(en)
|
2021-03-22 |
2024-05-23 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
IL307257A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
|
|
CN117858719A
(zh)
|
2021-03-29 |
2024-04-09 |
朱诺治疗学股份有限公司 |
使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
|
|
CN118201618A
(zh)
|
2021-04-16 |
2024-06-14 |
细胞基因公司 |
与bcma定向t细胞疗法的组合疗法
|
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
|
US20250304915A1
(en)
|
2021-05-25 |
2025-10-02 |
Institut Curie |
Myeloid Cells Overexpressing BCL2
|
|
WO2022261061A1
(en)
|
2021-06-08 |
2022-12-15 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
JP2025501272A
(ja)
|
2021-12-28 |
2025-01-17 |
ムネモ・セラピューティクス |
不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4463549A2
(en)
|
2022-01-14 |
2024-11-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
IL314801A
(en)
|
2022-02-22 |
2024-10-01 |
Juno Therapeutics Inc |
Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2023201133A1
(en)
|
2022-04-14 |
2023-10-19 |
Board Of Regents Of The University Of Nebraska |
Cell therapy for alzheimer's disease
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
JP2025521543A
(ja)
|
2022-06-22 |
2025-07-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
|
|
CA3260237A1
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
|
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
EP4554967A2
(en)
|
2022-07-12 |
2025-05-21 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
US20260027145A1
(en)
|
2022-07-27 |
2026-01-29 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
EP4565262A2
(en)
|
2022-08-05 |
2025-06-11 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
US20260061051A1
(en)
|
2022-08-26 |
2026-03-05 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
|
KR20250061756A
(ko)
|
2022-09-08 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
|
|
JP2025531268A
(ja)
|
2022-09-19 |
2025-09-19 |
チューン セラピューティクス インコーポレイテッド |
Ｔ細胞機能を調節するための組成物、システム、および方法
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
US20260166082A1
(en)
|
2022-11-02 |
2026-06-18 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
CN121100267A
(zh)
|
2022-12-09 |
2025-12-09 |
朱诺治疗学股份有限公司 |
使用全息成像预测细胞表型的机器学习方法
|
|
US20260207667A1
(en)
|
2022-12-13 |
2026-07-23 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024182516A1
(en)
|
2023-02-28 |
2024-09-06 |
Juno Therapeutics, Inc. |
Cell therapy for treating systemic autoimmune diseases
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
EP4716851A2
(en)
|
2023-05-23 |
2026-04-01 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
EP4754248A1
(en)
|
2023-07-31 |
2026-06-10 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
CN121909284A
(zh)
|
2023-07-31 |
2026-04-21 |
图恩疗法股份有限公司 |
用于调节il-2基因表达的组合物和方法
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
EP4777540A1
(en)
|
2023-09-13 |
2026-07-22 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
KR20260088542A
(ko)
|
2023-10-06 |
2026-06-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d-표적화 car을 발현하는 세포 요법을 사용한 조합 요법 및 관련 방법 및 용도
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2026008700A1
(en)
|
2024-07-03 |
2026-01-08 |
Immunofusion Bv |
Il7r alpha signalling domain, chimeric antigen receptor and uses thereof
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026020055A2
(en)
|
2024-07-18 |
2026-01-22 |
Juno Therapeutics, Inc. |
Methods for assessing exosomes in a cell composition and related uses
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|
|
WO2026064753A1
(en)
|
2024-09-23 |
2026-03-26 |
Tune Therapeutics, Inc. |
Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
|
|
WO2026161895A1
(en)
|
2025-01-27 |
2026-07-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression
|